title: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study.
abstract: OBJECTIVE
  To compare 2 treatment strategies in a prospective 5 year study of patients with rheumatoid arthritis (RA): early treatment with slow acting antirheumatic drugs (SAARD) versus a "wait and see" attitude.
  
  
  METHODS
  One hundred thirty-seven patients with RA of < 2 years' duration entered a double blind placebo controlled study: patients in the "early" (E) group were treated with auranofin within one year of diagnosis of RA, and SAARD treatment in the initially placebo treated group was delayed 8 months compared with the former group. [The results after 2 years clearly favored early treatment (Borg G, Allander E, Lund B, et al: J Rheumatol 1988; 15:1747-54)].
  
  
  RESULTS
  After a total observation period of 5 years in 75 representative patients, continued improvement in the E group was demonstrated, and differences between the 2 groups were maintained with regard to clinical variables, outcome measures, and radiographic evaluation.
  
  
  CONCLUSIONS
  The results indicate the existence of a therapeutic window in RA within the first 2 years of the disease.
authors.affiliation: Department of Rheumatology, Gentofte University Hospital, Hellerup, Denmark.
authors.forename: C
authors.initials: C
authors.lastname: Egsmose
authors.forename: B
authors.initials: B
authors.lastname: Lund
authors.forename: G
authors.initials: G
authors.lastname: Borg
authors.forename: H
authors.initials: H
authors.lastname: Pettersson
authors.forename: E
authors.initials: E
authors.lastname: Berg
authors.forename: U
authors.initials: U
authors.lastname: Brodin
authors.forename: L
authors.initials: L
authors.lastname: Trang
mesh_terms: D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D001310:Auranofin / Q000008:administration & dosage*; D004185:Disability Evaluation; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D018737:Hand Strength / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy; D010338:Pathology, Clinical; D011446:Prospective Studies; D011859:Radiography; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D001310:Auranofin